Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?

To: Wilfredo Pagani who wrote (598)	3/27/1998 10:18:00 AM
From: Henry Eichorszt	Respond to of 965

TO ALL: LEHMAN BROTHERS ON CNTO 3/27/98 -reit strong buy, raised estimates target $65

To: Wilfredo Pagani who wrote (598)	3/27/1998 10:28:00 AM
From: FNS	Read Replies (2) \| Respond to of 965

Dr. Pagani: Thanks for your comments on Avakine. It appears that approval may not be 'cut and dry' due to "finding right dosage and timing". re: <<My concern is that to find the right dosage and timing for treatment it will take sometime....>> This concerns me and I'm sure others on this thread are/would be con concerned...this may also be a factor in obtaining an Avakine partner, or perhaps CNTO may market it themselves via the Retavase distributor base...not sure where this all stands!!! Does anyone have any medical input as to Avakine (Bruce, you there?) and also how Avakine will be marketed? MY IMMEDIATE CONCERN IS THAT IF FDA COMES BACK WITH A 'DELAY' THEN THE STOCK WILL TANK...IT'S IMPORTANT THAT THE SHAREHOLDERS REALIZE IMPLICATIONS OF THIS DRUG...TOO MUCH FUTURE HOPES FOR ARTHRITIS ALSO A QUESTION! From a TA perspective, the stock has digested SSB's downgrade nicely via finding support at 40 and has bounced back nicely...some weak hands are out but now have yet to test 44+ resistance. Have a good day, FNS